A shares will usher in the first trading day of the year of the tiger tomorrow and the first batch of new shares in the year of the tiger.
According to the IPO arrangement, six new shares will be subscribed in Shanghai and Shenzhen next week. Among them, the new shares of Hefu China on the main board of Shanghai stock market next Monday, with an issue price of less than 5 yuan. Data show that low-cost new shares tend to rise higher after listing; Hualan vaccine, a new share of gem next Tuesday, is a leading manufacturer in China’s vaccine industry.
subscription of the first batch of new shares in the year of the tiger
There will be two new shares to be purchased next Monday, which are the catalyst in the new shares of Hefu China on the main board of Shanghai Stock Exchange and the new shares of science and innovation board.
Hefu China is a channel provider in the field of medical circulation. Its issuance price is 4.19 yuan / share, the issuance P / E ratio is 22.99 times, and the reference Industry P / E ratio is 18.74 times. Dingge subscription needs to be matched with the market value of 390000 yuan in Shanghai.
Statistics show that Hefu China has established cooperative relations with major in vitro diagnostic reagent projects of more than 100 tertiary hospitals to provide intensive procurement services of in vitro diagnostic products to hospitals. In terms of performance, during the reporting period (January September of 2018, 2019, 2020 and 2021), the company realized net profits of 67 million yuan, 67 million yuan, 73 million yuan and 54 million yuan respectively. The company expects to achieve a net profit of 79 million yuan to 83 million yuan in 2021, an increase of 8.92% to 14.37% over 2020.
According to past experience, low-cost new shares tend to rise higher after listing. In 2021, among the stocks listed on the main board of Shanghai and Shenzhen stock exchanges, a total of 14 stocks were issued at a price lower than 5 yuan / share. After listing, an average of 8.5 one word limit boards were harvested, of which the number of one word limit boards of 8 stocks reached or exceeded 10.
China catalyst is the leader of China’s special catalyst, with an issue price of 41.90 yuan / share, an issue P / E ratio of 85.98 times, and a reference Industry P / E ratio of 42.78 times. Dingge’s subscription needs to be matched with a market value of 110000 yuan in Shanghai. China catalyst plans to raise 784 million yuan this time, while the actual net fund-raising reaches 1.691 billion yuan, and the over raising multiple is 2.16 times.
According to the data, China catalyst is mainly engaged in the R & D, production and sales of special molecular sieves and new catalytic materials, as well as chemical technology and chemical process services. In terms of performance, during the reporting period (January September of 2018, 2019, 2020 and 2021), the company realized net profits of 09 million yuan, 53 million yuan, 92 million yuan and 116 million yuan respectively. The company expects to achieve a net profit of 124 million yuan to 144 million yuan in 2021, an increase of about 35.02% to 56.80% over 2020.
the leader of China’s vaccine industry
Hualan vaccine, a new share of the gem to be purchased next Tuesday, is a leading manufacturer in China’s vaccine industry.
The issue price of Hualan vaccine has not been announced yet. Dingge’s subscription needs to be matched with a market value of 65000 yuan in Shenzhen. Hualan vaccine plans to issue 40.01 million shares to the public, and it is expected to raise 2.526 billion yuan. According to this calculation, the issue price may reach about 60 yuan.
Statistics show that as China’s largest R & D and production enterprise of influenza vaccine, Hualan vaccine has focused on the R & D and production of human vaccine for many years. The production capacity, sales volume and market share of influenza vaccine rank first in China for several consecutive years. The listed products of the company include viral vaccine, bacterial vaccine and gene recombinant vaccine.
In terms of performance, the company achieved net profits of 270 million yuan, 375 million yuan, 925 million yuan and 528 million yuan respectively during the reporting period (2018, 2019, 2020 and January September 2021). The company expects to achieve a net profit of 740 million yuan to 1017 million yuan in 2021, a change of – 20% to 10% compared with 2020.
According to the prospectus disclosed by Hualan vaccine on January 24, the controlling shareholder of the company is Hualan Biological Engineering Inc(002007) mainly engaged in the R & D, production and sales of blood products, with a shareholding ratio of 75%. In addition, Henan Gaoling Huaying enterprise management consulting partnership (limited partnership) (hereinafter referred to as “Gaoling Huaying”) holds 9% shares of Hualan vaccine, and Xinxiang Chenyi Qiming management consulting partnership (limited partnership) (hereinafter referred to as “Chenyi Qiming”) holds 6% shares of the company.
Hualan Biological Engineering Inc(002007) said on the investor interaction platform on January 29 that Hualan vaccine is still the holding subsidiary of the company and will still be incorporated into the financial statements of Hualan Biological Engineering Inc(002007) .
Tianyan check shows that the three shareholders of Gaoling Huaying are Shenzhen Gaoling Tiancheng phase III Investment Co., Ltd., Shenzhen Gaoling Muqi equity investment fund partnership (limited partnership) and Shenzhen Gaoling Kunqi equity investment fund partnership (limited partnership). Among them, Shenzhen hilling Muqi equity investment fund partnership (limited partnership) holds nearly 90% of the shares, and the largest shareholder of the enterprise is Shenzhen Tencent industrial investment fund Co., Ltd., holding 34.18%.
List of new share subscription information next week
Hefu China: mainly engaged in intensive business of in vitro diagnostic products, circulation of medical products and other value-added services
Catalyst in : is mainly engaged in the R & D, production and sales of special molecular sieves and new catalytic materials, as well as chemical technology and chemical process services
Hualan vaccine: is mainly engaged in the R & D, production and sales of human vaccines
advertised shares: is mainly engaged in the R & D, production and sales of a series of products such as automobile nylon pipes and connectors
Biyi shares: is mainly engaged in the design, manufacture and sales of heating kitchen small household appliances such as air fryer, air oven, fryer and fryer
Jinhui shares: is mainly engaged in the mining and trading of non-ferrous metals
